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Abstract
Background: Pictorial blood loss assessment charts (PBACs) represent the most widely used method to assess
menstrual blood loss (MBL) in clinical trials. The aims of this review were to: (1) determine the diagnostic accuracy
of PBACs that have been validated against the reference alkaline hematin technique; (2) categorize the pitfalls of
using obsolete and nonvalidated charts; (3) provide guidelines for development of a new PBAC or use of an
existing chart to measure MBL in clinical trials; and (4) consider the feasibility of using pictorial charts in primary
care.
Methods: A literature review was conducted using Embase and MEDLINE databases. The review identified reports
of women with self-perceived or actual heavy menstrual bleeding (HMB), bleeding disorders, abnormal uterine
bleeding, leiomyomata (uterine fibroids) or endometriosis, and women undergoing treatment for HMB, as well as
those with normal menstrual periods. Data were reviewed from studies that focused on the development and
validation of PBACs and from those that used derivative noncertified charts to assess HMB.
Results: Nine studies reported validation of PBAC scoring systems against the alkaline hematin technique. Across
these studies, the sensitivity was 58–97%, the specificity was 7.5–95.5%, the positive and negative likelihood ratios
were 1.1–13.8 and 0.14–0.56, respectively, and the diagnostic odds ratio was 2.6–52.4. The cut-off score above
which the diagnosis of HMB was made ranged from 50 to 185. Several modifications of these PBACs were used in
other studies; however, objective confirmation of their validity was not reported. Overall, there was widespread
inconsistency of chart design, scoring systems, diagnostic cut-off limits and post-treatment outcome measures.
Conclusions: PBACs are best suited to the controlled and specific environment of clinical studies, where clinical
outcome parameters are defined. The current lack of standardization precludes widespread use of the PBAC in
primary care.
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Background
Heavy menstrual bleeding (HMB) is a common
gynecological condition that adversely affects quality of
life and work productivity. Approximately 10–35% of
women report heavy menstrual periods at some stage
during their reproductive years, with 5% consulting a
medical practitioner for investigation of HMB [1]. In re-
search, HMB is defined as a measured menstrual blood
loss (MBL) of > 80mL per cycle, but studies have repeat-
edly shown that at least 40% of women seeking medical
attention for heavy periods lose less than this volume
[2–5]. In clinical practice, the decision to treat is usually
based on a woman’s self-reported symptoms and the ef-
fect of these symptoms on quality of life rather than any
objective measurement, which concurs with current
guidelines for management of HMB [6]. However, self-
perception of menstrual loss is unreliable [4, 7].
Many clinical trial protocols require treatment efficacy
for HMB to be determined by quantitative changes in
MBL before a license can be granted for a new drug or
surgical procedure. The perceived gold-standard method
to measure MBL is the alkaline hematin (AH) technique,
which was established in 1964, with later modifications [3,
8–12]. It is an expensive procedure that requires special-
ized laboratory facilities. Patients must collect, store and
then submit all their used feminine products for MBL
analysis, which may not be acceptable or feasible for many
women. Therefore, it is mainly confined to clinical trials
and the research setting to confirm or refute HMB and to
evaluate efficacy of medical or surgical treatments.
An alternative semiquantitative method uses a pictor-
ial blood loss assessment chart (PBAC) to assess MBL.
This simple, inexpensive tool comprises a visual scoring
system that depicts a graded series of soiled tampons
and/or towels. The patient can directly record the num-
ber of her used feminine items and the degree to which
they are bloodstained. Since its inception in 1990, the
PBAC has become increasingly accepted by regulatory
bodies as a substitute for the AH technique [13] and is
now the most widely used method in clinical studies to
confirm HMB and to measure response to treatment
[14, 15]. It has also been used to measure postpartum
blood loss [16, 17], to screen women for investigation of
hemostatic disorders for which HMB may be a key
symptom (e.g. von Willebrand disease) [18–20] and to
evaluate the cost-effectiveness of different therapies for
HMB [21, 22]. Two studies have used a pictorial chart to
measure an increase in MBL after treatment of amenor-
rhea, or infrequent menstrual periods, with agents con-
taining herbal preparations [23, 24].
To validate any method, it is crucial to have a standard
against which the index test can be objectively judged.
The AH technique is the most obvious comparator for the
PBAC, but it only measures the blood fraction of
menstrual discharge. Blood typically comprises approxi-
mately 50% of total menstrual volume, although this can
vary widely on individual soiled sanitary items, particularly
at extremes of menstrual loss [5, 25, 26]. However, femin-
ine towels and tampons absorb all menstrual flow. To
maintain parity with AH, validated PBAC icon scores rep-
resent blood loss, irrespective of the total fluid volume. In
this review, we identify studies that describe the validation
of key pictorial charts that have been used to measure
MBL. We highlight the diversity in their diagnostic accur-
acy, the lack of standardization in their application and
the pitfalls of using derivative noncertified PBACs. We
propose essential criteria to bear in mind when using or
validating a pictorial chart for study trials and consider the
feasibility of their application in routine clinical practice.
Methods
Recommendations for the validation and use of PBACs
were based on a systematic review of the electronic data-
bases Embase and MEDLINE in February 2018, and again
in November 2018. The review protocol was registered at
PROSPERO (https://www.crd.york.ac.uk/PROSPERO) in
March 2016: record number CRD42016030083. The
search terms and selection process are shown in Add-
itional file 1 and in Fig. 1. Articles were independently
screened by two of the authors (J.L.M. and C.S.) for inclu-
sion criteria. To be included in the literature review, arti-
cles were assessed for eligibility in terms of patients,
outcomes and study design. The initial objective was to
detect reports in which a pictorial chart had been used to
measure MBL. The search was then specifically focused
on studies that validated a PBAC against the AH method.
The primary outcome was defined as the diagnostic accur-
acy of pictorial charts to determine HMB compared with
objective quantitation; a volume of > 80mL measured by
the AH technique was considered to be diagnostic of ex-
cessive MBL [7]. The relevant data were extracted from
text, tables or figures within the reports, and the quality of
each study was evaluated using the QUADAS tool for the
quality assessment of diagnostic accuracy studies; see
Additional file 2 (Whiting et al. 2006 [27]). The diagnostic
accuracy of each validated chart was calculated in terms of
sensitivity, specificity, positive and negative likelihood ra-
tios (LR + and LR−, respectively), and diagnostic odds ra-
tio (DOR) [28]. In this setting, diagnostic accuracy was
defined as the ability of a PBAC to discriminate between
HMB and normal blood loss. Results that exceeded the
stated cut-off threshold were classed as positive (HMB
confirmed), and those below the threshold were classed as
negative (HMB excluded).
Results
From Embase and MEDLINE, 837 records were retrieved
on February 11, 2018, and a further 34 were retrieved on
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November 2, 2018. After removal of duplicates and articles
that did not validate a PBAC against the AH method, nine
validation studies were identified. Reported quality parame-
ters of the nine studies were generally satisfactory, and no
studies were considered to have a very high risk of bias
(Additional file 2). However, with one exception (Magnay
et al. 2014 [5]), it was unclear whether PBAC test scores
were interpreted without knowledge of AH results, and vice
versa (test review bias and reference review bias, respect-
ively). Also, it was unclear whether clinical information
would normally be available when the index test is used in
practice (clinical review bias). Statistical data for the indi-
vidual studies are summarized in Table 1. The pooled
population from these reports comprised 1347 women with
a wide spectrum of MBL levels. This corresponded to 1821
menstrual cycles for which AH data and self-assessed
PBAC scores were available. Across these nine studies, the
diagnostic threshold score ranged from 50 to 185. The sen-
sitivity was 58–97%, the specificity was 7.5–95.5%, the LR+
was 1.1–13.8 and the LR− was 0.14–0.56. The DOR was in
the range 2.6–52.4, with the menstrual pictogram (superab-
sorbent-polymer-containing [SAP-c] version) giving the
highest value [5]. It is generally accepted that the greater
the DOR, the better the discriminatory test performance.
However, measures of diagnostic accuracy are not fixed in-
dicators of test performance. The diagnostic accuracy of
one study may not apply to other patient groups and set-
tings – a fact that is often overlooked. It was not feasible to
pool data for meta-analysis because of the wide diversity in
patient demographics, HMB prevalence, sanitary products,
study procedures, cut-off scores and data analysis.
The nine validation studies are discussed below in
chronological order of publication, demonstrating the
processes required to develop and to certify a pictorial
method to measure MBL.
Early validation studies
The first PBAC was introduced in 1990 by Higham et al.
and depicted three images (icons) that represented spe-
cific brands of feminine items soiled with increasing
amounts of blood [29]. The icon scores were 1, 5 and 20
points for towels and 1, 5 and 10 points for tampons. A
range of blood volumes produced visually similar stain
sizes. Consequently, the score allocated to each icon was
related, but not necessarily equal, to the applied blood
volume in milliliters. The size of blood clots was com-
pared with the diameter of UK coinage, and the number
of flooding events was recorded, although there were no
associated scores. Twenty-eight women of undisclosed
menstrual status were monitored between one and 3 cy-
cles each, giving 55 patient-assessed cycles in total. The
PBAC scores ranged from 5 to 456 (median 121),
whereas MBL measured by the AH technique ranged
from 2 to 366 (median 74), giving a correlation coeffi-
cient (r) of 0.847. When used as a diagnostic test for
HMB, a score of ≥100 gave a reported sensitivity and
specificity of 86 and 89%, respectively. However, the
PBAC progressively underestimated blood volume as
menstrual loss increased, which demonstrated an im-
portant limitation of the method for women with HMB.
The Higham PBAC is shown in Fig. 2a.
This PBAC was reassessed in 1994, although women
were allowed to use their usual sanitary materials rather
than those initially validated. With a specificity of 52%,
it detected more false positives than the Higham study
[30]. A year later, a modified pictorial chart was certi-
fied for use with specific feminine products. The scor-
ing system was identical to the Higham PBAC, but the
icons looked different (Fig. 2b). Based on receiver oper-
ating characteristic analysis, a cut-off point of 185
showed the greatest positive and negative predictive
values for HMB, and it was concluded that a score of
> 185, rather than > 100, should be used as a diagnos-
tic threshold [31]. In 1999, adolescent Nigerian girls
tested a novel pictorial chart with four towel icons
(Fig. 2c). The sanitary products were not identified. Max-
imum sensitivity and specificity were achieved at a cut-off
score of only 50, which was attributed to the fact that all
Fig. 1 Database search and selection process. aAdditional references
to those previously identified
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the study population had normal MBL [32]. In 2000, the
validity of the PBAC was challenged when Reid et al. tried
to reproduce findings from the Higham pictorial chart on
a population of women with self-reported HMB. Based on
a specificity of 7.5% and a low correlation (r = 0.47) be-
tween PBAC score and AH, it was judged to be an in-
appropriate method to measure MBL [33].
In 2001, a new version of the PBAC was introduced
by Wyatt et al. The menstrual pictogram depicted five
icons representing blood loss on towels and four icons
for tampons. The method was validated using simu-
lated menstrual fluid (blood/saline, 1:1 ratio) to repre-
sent the physiological setting, in which the visible
stain typically comprises about 50% blood (J.L. Mag-
nay and K.M. Wyatt, personal communication). Scores
for blood clots and extraneous loss were included.
Crucially, all scores were quoted as blood volume with
a cut-off limit of 80 mL, which made it directly com-
parable to the AH technique. The pictogram was vali-
dated using specified towel and tampon brands with
various absorbency ratings (Fig. 2d) [34].
Later validation studies
Since these early validation studies, towel and tampon
manufacturers have responded to market demand for
more comfortable, discrete feminine products with en-
hanced fluid absorbency. Sanitary products used in the
early PBACs became obsolete, and ultra-slim towels
containing superabsorbent polymers rapidly gained
popularity. In 2011, an updated version of the Higham
chart was validated for Always Ultra towels (Proctor &
Gamble, Cincinnati, OH, USA), the most popular brand
of ultra-slim towel in the USA and UK [38, 39]. Tam-
pons, clots and episodes of flooding were not evaluated
so, to minimize extraneous loss, women were asked to
use double towels during episodes of HMB. Maximum
sensitivity and specificity were achieved at a cut-off
score of 150 [35]. Two years later, Larsen et al. revali-
dated the menstrual pictogram after obtaining identical
sanitary wear to that used in the original chart by Wy-
att et al. (J.L. Magnay and L. Larsen, personal commu-
nication). At a threshold of 80 mL, the method gave a
sensitivity of 96% and a specificity of 92% in dichotom-
izing response to medical treatment in terms of a ≥ 50%
or < 50% decrease in MBL. This was the first time a pic-
torial chart had been endorsed for other than diagnos-
tic purposes; namely, the MBL assessment of women
with uterine fibroids treated with an investigational
drug [36]. However, the validation was done with an
obsolete version of feminine items and cannot be ap-
plied to other studies. In 2014, a new menstrual picto-
gram (SAP-c version) was validated with simulated
menstrual fluid for use with Always Ultra towels and a
choice of three absorbencies (Fig. 2e). Correction
Table 1 Diagnostic accuracy of pictorial methods to determine heavy menstrual bleeding
Reference N subjects
(cycles)
Study population HMB
cut-off
score
Sanitary products Sensitivity,
%
Specificity,
%
LR+
ratio
LR−
ratio
DOR
Higham et al.
(1990) [29]
28 (55) NR 100 Kotex Simplicity 2
Tampax/Kotex Fems
Super Plus
86 89 7.8 0.16 49.7
Deeny et al. (1994)
[30]
53 (53) DUB 100 Not specified 88 52 1.8 0.23 7.9
Janssen et al. (1995)
[31]
288 (489) HMB or unexplained
anemia
185 Kotex Maxi Long
Tampax Super
62 95.5 13.8 0.40 34.6
Barr et al. (1999)
[32]
281 (281) Normal MBL 50 Not specified 58 75 2.3 0.56 4.1
Reid et al. (2000)
[33]
103 (103) Self-reported HMB 100 Kotex Simplicity 2
Tampax Super
97 7.5 1.1 0.40 2.6
Wyatt et al. (2001)
[34]
108 (108) Self-reported normal or
HMB
80mL Kotex Maxi Day & Night
Tampax Regular/Super/
Super Plus
86 88 7.2 0.16 45.0
Zakherah et al.
(2011) [35]
197(241) Self-reported
normal or HMB
150 Always Ultra
No tampons
83 77 3.6 0.22 16.3
Larsen et al. (2013)
[36]
170 (256) UF with HMB 80mL Kotex Maxi Day & Night
Tampax Regular/Super/
Super Plus
88 87 6.8 0.14 49.1
Magnay et al.
(2014) [5]
119 (235) Self-reported light, normal
or HMB
80mL Always Ultra Normal/
Long/Night
No tampons
82 92 10.3 0.20 52.4
N is the number of study subjects (number of menstrual cycles) for which data are available. DOR diagnostic odds ratio, DUB dysfunctional uterine bleeding, HMB
heavy menstrual bleeding, LR likelihood ratio, MBL menstrual blood loss, NR not reported, UF uterine fibroids
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factors were applied to the provisional icon scores to
account for the progressive increase in blood fraction
with menstrual volume, as demonstrated in Fig. 3 [5,
26, 40]. The cut-off value for HMB was 80 mL.
Nonvalidated PBACs
Several derivative PBACs were detected in our database
search but, with the exception of those described above,
objective confirmation of their validity was not reported.
Most charts referenced the scoring system of Higham et al.
and, to a lesser extent, Janssen et al., although several
modifications were made. The brand(s) of sanitary products
were stated for some PBACs [15, 41–45] but not for others
[46–65]. The icon illustrations were often different and/or
the individual scores were altered, whether by error or by
design [41, 43, 46–49, 51, 52, 55–57, 60–63, 66, 67].
In numerous cases, a validated PBAC was refer-
enced, but the cut-off threshold was adjusted for no
obvious reason [46, 55–57, 59, 64, 65, 68–72]. Two re-
ports directly compared the Higham and Janssen scor-
ing systems (HMB > 100 and > 185, respectively) in the
same study [73, 74]. In some instances, contemporary
towels and tampons were deliberately substituted for
their validated obsolete counterparts [16, 42, 75], but
the cut-off score was not re-established. For a given
volume, the visible stained area on modern sanitary
materials is less than on older products [75] and can
vary greatly between different brand formulations and
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a) PBAC, Higham et al. 1990 b) Janssen chart, Janssen et al. 1995
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Fig. 2 Examples of validated PBACs reported in the literature. PBAC pictorial blood loss assessment chart. a. The PBAC presented by Higham et al.
reproduced from British Journal of Obstetrics and Gynaecology, 97, Higham JM et al. Assessment of menstrual blood loss using a pictorial chart,
pp734–9, Copyright 2005, with permission from John Wiley and Sons [29]. b. The chart presented by Janssen et al. Adapted from Obstetrics &
Gynecology, 85, Janssen CA et al. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss,
pp977–82, Copyright 1995, with permission from Elsevier [31]. c. The pictorial chart presented by Barr et al. Reproduced from International Journal
of Gynecology & Obstetrics, 66, Barr F et al. A pictorial chart for managing common menstrual disorders in Nigerian adolescents, pp51–3, Copyright
1999, with permission from John Wiley and Sons [32]. d. The menstrual pictogram presented by Wyatt et al. Reprinted from Fertility and Sterility,
76, Wyatt KM et al., Determination of total menstrual blood loss, pp125–33, Copyright 2001, with permission from Elsevier; and adapted from
Obstetrician & Gynaecologist, 6, Warrilow G et al. Quantification of menstrual blood loss, pp88–92, Copyright 2004 Royal College of Obstetricians
and Gynaecologists, with permission from John Wiley and Sons [34, 37]. e. The chart presented by Magnay et al. Reprinted from Fertility and
Sterility, 101, Magnay JL et al. Validation of a new menstrual pictogram (superabsorbent polymer-c version) for use with ultraslim towels that
contain superabsorbent polymers, pp515–22, Copyright 2014, with permission from Elsevier [5]
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absorbency ratings [41, 75–78]. Four studies directly
converted PBAC score to MBL volume [17, 72, 79,
80]. However, this relationship is not linear because a
range of blood volumes may be assigned to the same
icon category. Three studies used a PBAC to simply
assess the pattern of menstruation before and after
treatment: the first to determine the length of men-
strual period [81], the second to additionally record
the number of towels used [82], and the third to meas-
ure the decrease in number of towels used at the time
of heaviest menstrual loss [83]. None reported mea-
sured MBL. Table 2 lists some examples of modified,
nonvalidated PBACs.
Discussion
Clinical trials often require a quantitative change in
MBL as evidence of treatment efficacy for HMB. If a
PBAC is used for this purpose, a decision must be made
whether to use a validated method or to develop a new
device. If the plan is to use an existing chart, attention
should be focused on those certified for modern prod-
ucts [5, 35]. Authors should try to identify the study de-
sign that most closely matches their own setting. The
prevalence of HMB in the reference PBAC report can be
used as a guide if that of the intended study population
is known [84].
With only two current charts to consider, the choice is
limited. However, development of a new pictorial chart
can significantly increase the cost and timeline of a
clinical trial. The fundamental requirements for the de-
sign and validation of a PBAC are listed in Table 3 and
should be carefully deliberated before a decision is made.
Due consideration should be given whether to include
scores for stained sanitary towels, stained tampons, men-
strual clots and extraneous blood loss/flooding episodes.
Many charts do not incorporate all these components,
including some validated methods (Table 4). Other key
factors are the construction and design, scoring system,
ease and practicality of use and limitations of the
method. Each of these elements is discussed below.
Components of a pictorial chart
Sanitary towels
All PBACs estimate MBL from feminine towels. Modern
towels have a layered design, consisting of a fluid-
permeable surface (topsheet), an absorbent core and an
impermeable backing with adhesive. The shape, absorb-
ency and size of the product may vary depending on the
manufacturer. The towel contour may be either flat or
curved, and with or without ‘wings’ which attach it se-
curely in place and add extra leak protection. Menstrual
fluid rapidly transfers to the absorbent core via a series
of micro-funnels, leaving the upper surface relatively dry
and stain free. The US Food and Drug Administration
(FDA) regulates sanitary towels as Class I Medical De-
vices subject to manufacturing controls and consumer
complaint management, but the absorbency ratings are
arbitrary and unregulated. Towels of similar size and/or
with the same stated absorbency category but from dif-
ferent manufacturers can have a wide range of fluid re-
tention capacities [77]. In ultra-slim formulations, MBL
may be captured by a thin collapsed polymeric foam
layer that expands and absorbs fluid upon contact [85]
or by superabsorbent polymer granules embedded in the
towel core (e.g. Always Ultra). The manner of stain
spread depends on the density and distribution of super-
absorbent particles throughout the absorbent zone,
which varies among towel brands. Modern thick maxi
towels are more efficient at absorbing fluid and limiting
stain spread than their former versions, as demonstrated
in Fig. 4 [75], although they are generally less popular
than ultra-slim products. A pictorial chart requires valid-
ation for a specific brand of feminine towel in a range of
absorbencies to accommodate different levels of MBL.
Tampons
Tampon designs have progressively improved to limit leak-
age of menstrual fluid. Because they are worn internally,
tampons are categorized by the US FDA as Class II Medical
Devices. The maximum fluid retention weight for each ab-
sorbency category is strictly controlled, and all brands at
the same rating must have the same maximum absorption
capacity. Although most brands of unused tampons look
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Fig 3. Median percentage blood fraction of menstrual fluid versus
icon category of menstrual pictogram (SAP-c version). Second-order
polynomial curve fit of median percentage blood fraction of
menstrual discharge, with respect to icon category of the menstrual
pictogram (SAP-c version); n = 3257 Always Ultra sanitary towels.
PBAC pictorial blood loss assessment chart, SAP-c superabsorbent-
polymer-containing. Reprinted from Fertility and Sterility, 101, Magnay
JL et al., Validation of a new menstrual pictogram (superabsorbent
polymer-c version) for use with ultraslim towels that contain
superabsorbent polymers pp515–22, Copyright 2014, with
permission from Elsevier [5].
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essentially similar, the shape and dimensions of a worn item
can vary considerably depending on the expansion and ab-
sorbency properties of the materials used. Figure 5 shows
examples of tampon shapes after the addition of fluid.
Using tampons during a menstrual period is less likely to
result in extraneous fluid loss. Some women prefer the op-
tion and added sense of security of wearing a tampon and
towel together because it gives greater personal choice; fur-
thermore, this may potentially lead to an increased likeli-
hood of patient recruitment and compliance in clinical
studies [5, 86]. However, some women do not like tampons,
particularly at times of heavy flow, and they are not in-
cluded in all PBACs. If tampon icons are featured, they
should represent the staining patterns produced by that
particular brand.
Menstrual clots
The blood volume of menstrual clots is difficult to
quantify. Clots can be quite gelatinous and contain
varying amounts of endometrial tissue and vaginal
Table 2 Examples of nonvalidated PBACs to determine MBL
Publication N Sanitary products Deviation from validated PBAC Validated cut-off score
for HMB
PBAC
referenced
Biri et al. (2008) [46] 600 NR • Icon-3 tampon score = 20
• Cut-off score = 50
100 Higham
Rott et al. (2009) [47] 46 NR • Icon-3 tampon score = 15
• Icons different
100 Higham
Kouides et al. (2009) [42] 116 Kotex Curved Maxi
Tampax Super
• Towel and tampon brands 100 Higham
Hacioglu et al. (2016) [61] 90 Free to choose • Icons different 185 Janssen
Herman et al. (2016) [65] 900 NR • Cut-off score = 150 100 Higham
Jacot-Guillarmod at el.
(2010) [49]
N/A NR • Icon-3 tampon score = 20
• Icons different
100 Higham
Lopes et al. (2010) [41] Lab
tests
Kotex Ultraslim • Icon-3 towel score = 10
• Icons different
100 Higham
Nahidi et al. (2011) [55] 160 NR • Icons different
• Cut-off score quoted as 80 mL
100 Higham
Donnez et al. (2015) [54] 242 ‘Standardized’,
brand not identified
• Clots equated to circle diameters 100 Higham
Dasharathy et al. (2012)
[57]
201 Free to choose • Number of towel icons = 4
• Icons different
• Cut-off score = 72.5
80 mL Wyatt
Hashim et al. (2012) [15] 95 Always Ultra Core Plus • Towel brand 185 Janssen
Goshtasebi et al. (2013)
[44]
90 Panberes • Towel brand 185 Janssen
Hald et al. (2014) [56] 429 Free to choose • Icons different
• Cut-off score = 160
100 Higham
Mawet et al. (2014) [43] 280 Always Ultra
Normal/Super Plus
• Towel brand
• Icons different
80 mL Wyatt
Brôlmann et al. (2016) [59] 50 NR • Cut-off score = 120 80 mL Wyatt
Ashraf et al. (2017) [60] 152 NR • No stains on towel icons 1 and 3 or
tampon icon 3
100 Higham
Han et al. (2018) [71] 95 NR • Cut-off score = 130 185 Janssen
Gopimohan et al. (2015)
[69]
45 Stayfree Secure Regular • Cut-off score = 100 150 Zakherah
Gorgen et al. (2009) [64] 60 Unknown • Cut-off score = 75 100 Higham
Barrington et al. (1997)
[62]
50 ‘Same brand used’
Not identified
• Icons different
• Scoring system different
100 Higham
Van Dongen et al. (2009)
[72]
21 NR • Cut-off score = 200 100 Higham
Kashefi et al. (2015) [63] 71 ‘Same towels used’
Not identified
• Icon-3 tampon score = 20 NR Higham
N is the number of participants in study for which data are available. HMB heavy menstrual bleeding, MBL menstrual blood loss, NR not reported, PBAC pictorial
blood loss assessment chart
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secretions. The blood component cannot be verified
by AH unless captured on sanitary wear and isolated
for analysis. Many PBACs omit this element
altogether [5, 33, 36, 47, 51, 56, 57, 87]. Some charts
compare clot sizes to specific coinage [29, 31, 88] or
to full-sized icons of stated diameters [54] (Fig. 6).
The Wyatt pictogram depicts clots as a series of ir-
regular shapes, but there is no associated size com-
parator [37]. Other PBACs use a subjective
description of size – e.g. ‘small’ or ‘big/large’ – or
just a ‘yes/no’ response, without reference to any
measurable standard [32, 48, 49, 55]. Menstrual clot
scoring is theoretically suitable for electronic ver-
sions of the PBAC if images are presented as actual-
sized screenshots.
Extraneous blood loss (flooding episodes)
Extraneous blood loss is the passage of menstrual fluid
that is not captured by a sanitary product. It can occur
at times of excessive MBL, when the absorption capacity
of the sanitary item is exceeded, or when there is noth-
ing to absorb the menstrual flow, e.g. while bathing
without a tampon inserted in the vagina. Opinions differ
as to whether extraneous loss significantly contributes to
the overall volume of menstrual discharge [7, 31, 32, 34],
although it may be an important factor in influencing
how women perceive their MBL. Noncaptured extrane-
ous MBL is difficult to quantitate accurately because it
cannot be measured by the AH technique. Most vali-
dated PBACs do not include flooding episodes (Table 4),
nor do many derivative charts [47, 49, 51, 52, 56, 87].
Some require women to simply record the number of
flooding events [41, 48] or to allocate 5 points for each
flooding episode, regardless of severity [88, 89]. The Wy-
att pictogram judges extraneous loss by scoring the
graded decrease in visibility of a coin placed in the base
of a toilet pan when incremental volumes of blood are
added [34]. However, in the everyday setting, this meas-
urement would depend on the dimensions of the toilet
receptacle, the volume of diluting water and the avail-
ability of (nonretrievable) coins to perform the test.
Scoring system
All included components of a PBAC should be assessed.
The value assigned to individual towel and tampon icons
should be verified against AH for every selected absorb-
ency category. Allocating blood volumes to each icon (as
opposed to an empirical value) allows direct assessment of
MBL, as in the menstrual pictogram. Whichever scoring
system is used, it must be sufficiently sensitive to detect
what are considered to be clinically relevant differences in
MBL at the appropriate time point following treatment
for HMB. An important issue to consider is the increase
in stain area when a feminine towel or tampon is sub-
jected to mechanical load [75]. Compression forces
exerted by the wearer may ultimately affect icon selection.
Choosing products that show minimal stain spread under
pressure would limit this confounding element [5, 86].
Other factors that can affect visible stain area are the rate
and composition of menstrual flow, individual anatomy,
physical activity and posture. It is difficult to control for
these variables.
The PBAC must be tested by a spectrum of women
with light, normal and heavy MBL to assess not only its
validity as a diagnostic tool for HMB but also its ability
to estimate normal and low menstrual volumes. Many
women who complain of HMB actually have normal pe-
riods, and those with excessive blood loss often experi-
ence dramatic reductions in MBL after treatment. The
Table 3 Key requirements for the design and validation of
PBACs
• Towel and tampon scores must be validated against the AH method
• Scores must be validated for specific towel/tampon brands and for
each absorbency category shown on the chart
• To prevent mis-scoring or confusion, there must be clear visual differ-
ences between successive icons
• To assess reproducibility during validation, icon scores should be
subjected to repeated testing by different women
• The chart must be validated for all levels of MBL (low, normal and
high)
• The method should be able to detect clinically relevant differences in
MBL following treatment
• The chart design should be simple, straightforward and user friendly,
and patients should be thoroughly briefed in its use, particularly in the
interpretation of nonstandard staining patterns
• After validation, the format, size and appearance of the chart should
not be changed because this may alter a woman’s perception of
scoring
• A paper-based version should be conveniently sized and of robust
construction. If an electronic version is used, women should be aware
of the protocol in cases of data transmission failure
AH alkaline hematin, MBL menstrual blood loss, PBAC pictorial blood loss
assessment chart
Table 4 Components included or excluded in validated
pictorial methods to assess MBL
Reference Component
Towels Tampons Clots Flooding
Higham et al. (1990) [29] ✓ ✓ ✓ ✓
Deeny et al. (1994) [30] ✓ ✓ Not known Not known
Janssen et al. (1995) [31] ✓ ✓ ✓ X
Barr et al. (1999) [32] ✓ X ✓ X
Reid et al. (2000) [33] ✓ ✓ X X
Wyatt et al. (2001) [34] ✓ ✓ ✓ ✓
Zakherah et al. (2011) [35] ✓ X X X
Larsen et al. (2013) [36] ✓ ✓ ✓ X
Magnay et al. (2014) [5] ✓ X X X
MBL menstrual blood loss
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scores should be reproducible and yield the same results
in repeated applications [86].
Construction and design
The format of a validated PBAC should not vary during use
because it may change a patient’s perception of her MBL
and, thus, her score. Because towels and tampons often
have distinctive shapes and sizes, icon images need to rep-
resent the feminine items used [5, 86]. Successive icons
must display clear differences in appearance to avoid in-
decision or mis-scoring. If a paper-based PBAC is chosen,
the chart and menstrual diary should easily fit into a typical
daytime-sized handbag and have a neutral, discrete cover. It
must have a robust construction to prevent disintegration
and allow sufficient room for the number of soiled feminine
items to be recorded each day [86]. Prospective daily re-
cording is critical for data collection involving a series of
recurrent similar events such as MBL, in which the accur-
acy of retrospective recall tends to be low [90].
If an electronic design is preferred (e.g. a dedicated eDi-
ary, smartphone application or website), a paper version
may still be needed in situations in which telephone or
Internet reception is unavailable, the equipment has insuf-
ficient battery charge, or it has been lost or damaged. Elec-
tronic recording of MBL is not a new concept. In 2002, a
menstrual symptometrics device for use by patients incor-
porated a menstrual pictogram programmed into an
Amstrad PDA600 PenPad [91]. It was validated for MBL
measurement using the paper-based chart of Wyatt et al.
as the reference standard [34]. Electronic data logging is
generally preferred by patients and results in fewer miss-
ing data than a paper calendar and fewer transcription er-
rors when results are transferred to a computer database
[90]. A study showed that 80% of adolescents and young
women preferred to use a smartphone application version
Fig. 4. Measured blood volumes compared with the menstrual pictogram scores. Known volumes of blood were applied to Kotex Regular maxi
towels to produce similar stain sizes to those depicted by the highlighted icon scores on the menstrual pictogram of Wyatt et al., which was
validated using an older, obsolete version of the same sanitary product. The difference in volume required and the effect of towel compression
on stain area are shown. MP menstrual pictogram. Reprinted from a poster with permission from the author: Burnett PE et al., Comparison of
Menstrual Pictogram Scoring to the Validated Alkaline Hematin Assay as Techniques for Measuring Blood Loss on Feminine Hygiene Products [75]
LeakGuard
braid
LeakGuard
skirt
Tampax PearlTampax Cardboardo.b. ProComfort
Fluid-Lock
grooves
Fig. 5 Examples of menstrual tampon shapes after addition of fluid. Anti-leak features of each tampon type are shown. When wet, o.b.
ProComfort tampons swell radially to form a barrel shape, Tampax Cardboard tampons enlarge axially with minimal radial expansion and Tampax
Pearl tampons expand to produce a winged profile. o.b. ProComfort tampons, Edgewell Personal Care, St Louis, MO, USA; Tampax tampons,
Proctor & Gamble, Cincinnati, OH, USA
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of the PBAC over a paper-based chart, although the
method was limited by mobile technology issues [92]. A
second study developed an electronic PBAC (ePBAC) that
could be completed using the Internet [93]. Neither chart
had been validated against the AH method.
Ease and practicality of use
To gain maximum patient compliance, use of the PBAC
must be as straightforward as possible. At an early stage,
patients’ views should be sought about the method and
how it may be improved, and the level of compliance
should be tested [86, 92]. Women should be supplied
with sufficient feminine materials, based on their ex-
pected MBL, and carefully instructed on how to score
their soiled items. This includes interpretation of non-
standard or fragmented staining patterns. The import-
ance of prospective recording must be emphasized, and
the contact details of a liaison nurse should be available
in case of any concerns.
Extraneous MBL is common for women experiencing
HMB and may be due to sudden flooding episodes, not
changing sanitary products often enough or a combin-
ation of both. To limit this event, women should be en-
couraged to use tampons and towels concurrently, to
ensure a fresh tampon is worn when showering/bathing
or visiting the toilet and to change their feminine items
as frequently as possible at times of heavy menstrual
flow. If a woman does not wish to use tampons, she
should choose towels with the highest absorbency rating
and try to replace them before saturation occurs.
Recognition of limitations
All diagnostic methods have limitations, particularly
those with a subjective element. Each PBAC image is al-
located a specific score, but patients may assign a range
of blood volumes to the same icon category. The choice
of icon may be influenced by whether a woman per-
ceives her menstrual loss to be light, normal or exces-
sive. A visual rating system is not as accurate as the AH
method, which provides a definitive blood volume and
does not rely on individual perception of MBL or errors
in selecting or recording the correct icon. Pictorial
charts may overestimate low volumes of MBL because
whole blood represents a smaller proportion of the vis-
ible stain area than at normal and high volumes (Fig. 3).
Conversely, the score assigned to the highest icon cat-
egory can markedly underestimate MBL because of a
ceiling effect as a sanitary item becomes fully saturated.
A potential drawback of using modern towels is the
difficulty of visualizing the bloodstained area on the
upper surface, because fluid is rapidly transferred to the
interior region. The SAP-c menstrual pictogram over-
comes this problem by scoring the stain on the under-
side of the towel, where it is clearly visible [5, 86]. Many
stain profiles will not conform to the standardized PBAC
icons [5, 94]. Stains may be fragmented or a completely
different shape, which could potentially result in under-
estimation or overestimation of MBL, depending on per-
sonal perception of the soiled area.
Apart from the diversity in diagnostic accuracy – a fact
highlighted by validated PBACs – there is a lack of
standardization in measuring post-treatment outcomes.
The aim of therapy is to improve a patient’s well-being
to an acceptable level, but the relationship between qual-
ity of life and a clinically meaningful decrease in MBL
UK currency
Higham et al. 
1990 
1 point
2.0 cm
(penny)
1 point
1.9 cm
(5 cents)
2.0 cm
Small clots/
flooding
3.0 cm
Large clots/
flooding
1 mL
1 mL
3 mL
5 mL
1.8 cm
(dime)
3 mL
1.9 cm
(cent)
5 mL
2.4 cm
(quarter)
5 points
3.2 cm
(50 cents)
5 points
3.0 cm
(50 pence,
pre-1997)
5 points
2.7 cm
(50 pence,
post 1997)
Australian currency
Dennie & Grover, 
2009
US currency
Repros 
Therapeutics
Circles  
Donnez et al. 
2015
Scoring for the Wyatt 
menstrual pictogram, 
as presented by 
Warrilow et al. 2004
(Actual sizes not known)
Fig. 6 Examples of PBAC clot scoring icons. Actual-size diameters
shown (cm) [29, 37, 52, 54, 88]. PBAC pictorial blood loss assessment
chart. Clot scoring adapted from Obstetrician & Gynaecologist, 6,
Warrilow G et al., Quantification of menstrual blood loss, pp88–92,
Copyright 2004 Royal College of Obstetricians and Gynaecologists,
with permission from John Wiley and Sons
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remains unresolved. With a single exception, pictorial
charts have not been validated as a tool to test the ef-
fectiveness of therapy [36], and researchers have had to
define their own criteria for treatment success. Some
have stipulated a decrease in PBAC score to below the
chosen HMB cut-off value [95] or by a certain number
of points from the baseline measurement of MBL, e.g.
50 points [15, 96–98]. Others have advocated a percent-
age reduction in score; values of 20–50% have been re-
ported [36, 58, 59, 63, 99–105]. If the treatment goal is
amenorrhea (PBAC score < 2), the endpoint is clearly de-
fined [54, 106–109]. The aim of several reports is just to
detect a significant difference in MBL reduction between
different treatments for HMB.
The appropriate time point to test efficacy will need to
be considered, subject to the type and purpose of ther-
apy. Medical treatments designed to rapidly reduce MBL
tend to have short follow-up times of between 1month
and 12months [44, 110–113], whereas surgical interven-
tions, such the levonorgestrel intrauterine system and
endometrial ablation, are designed for long-term reduc-
tion of MBL. Monitoring of menstrual loss has been re-
ported for up to 5 years after surgery at various time
intervals, depending on the study [59, 106, 107, 114].
The post-treatment time point(s) for MBL measurement
should be clearly defined in the trial design.
Use of pictorial blood loss assessment charts in primary
care
The role of PBACs in primary care is currently unclear.
The usual procedure to assess MBL combines a woman’s
self-perception of her menstrual flow (in terms of light,
normal or heavy) with hemoglobin level and/or men-
strual markers, such as length of period, number of used
sanitary products, number of days of ‘heavy’ bleeding,
number of flooding episodes and size of clots passed.
Together with quality-of-life issues, this subjective ap-
proach is often the only trigger for medical and surgical
interventions, although it is unreliable [2, 31, 76].
Measurement of MBL by the AH technique is obvi-
ously impractical in this setting, but a simple, semi-
objective method would be a useful diagnostic tool. It
could clarify the patient’s complaint and also influence
the choice and expectations of treatment. Historical
research data have shown that some women whose
MBL has been shown to be normal can be dissuaded
from seeking unnecessary therapy for perceived HMB
[3, 115, 116]. A fully validated PBAC is theoretically
suitable for this purpose, combined with a daily diary
to document responses to specific health-related ques-
tions throughout the menstrual cycle. This day-to-day
record would have the dual purpose of assessing both
symptom severity and the impact of perceived or ac-
tual HMB on everyday life, which would comply with
the National Institute for Health and Care Excellence
(NICE) guidelines to assess quality-of-life issues for
women with excessive blood loss. Although NICE
guidelines do not recommend routine quantitation of
MBL, they do acknowledge that further research into
indirect measurements of MBL in primary and sec-
ondary care is warranted [6].
Some studies have recommended the use of a PBAC
in primary care to increase the diagnostic accuracy of
HMB [35, 36, 46], possibly as an adjunct to clinical his-
tory and menstrual markers [65, 117, 118]. However,
widespread application of this method is currently lim-
ited by a lack of expert consensus regarding the choice
of pictorial chart, the diagnostic cut-off score for HMB
and clear objective criteria in the assessment of post-
treatment clinical outcome.
At a practical level, the chart would require at least
one menstrual cycle to complete. Results would not
normally be available during a first consultation, unless
a PBAC had been completed beforehand by prior ar-
rangement with the healthcare center. A dedicated
women’s clinic might suit this purpose, in which a nurse
practitioner could train patients to use a validated
PBAC, distribute the required sanitary protection and
address any queries or anxieties [119]. Some women
may be discouraged because of the inevitable delay in
diagnosis, the rigorous attention to detail required when
scoring MBL, the stipulation to change sanitary wear
frequently to avoid leakage (which might not always be
possible) or the need to use specified and possibly un-
familiar sanitary products. A diagnostic ‘primary care’
PBAC that has been validated for a range of popular
sanitary products, particularly those designed for heavy
menstrual flow, together with appropriate instruction
and support may help to alleviate these concerns. Also,
the widespread availability and popularity of smart-
phones opens the possibility of developing ePBACs that
would be acceptable to patients. However, this area has
yet to be explored.
Conclusions
Pictorial blood loss assessment charts are increasingly
being used in clinical trials to diagnose HMB and to
evaluate efficacy of new treatments, despite the fact that,
in most cases, their accuracy has not been validated with
modern sanitary materials. We have highlighted some
key factors to consider when using this method in the
contemporary research setting. We hope that this review
will act as a basic guide for researchers who wish to use
a PBAC to assess MBL, whether for selection of the
most appropriate validated method or the creation of a
new chart tailored to the requirements of their study.
Feminine hygiene technology will continue to advance,
and the market should be constantly monitored for
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product updates. New devices for electronic data capture
will also be developed and may become the method of
choice for recording patient results. Pictorial charts must
keep pace with these changes and be revalidated accord-
ingly if they are to remain the chosen tool to assess
MBL in clinical research. With these caveats in mind, we
suggest that the PBAC can be a useful tool to determine
MBL under defined and controlled study conditions.
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